Therefore, subsequent phase III trials had only evaluated the predictive efficacy of atezolizumab based on the IC-derived PD-L1 which was defined as a percentage of tumor area (consisting of TC and associated intra-tumoral and continuous peri-tumoral stroma) occupied by IC with discernible PD-L1 staining of any intensity (16, 18). Here, CD274 is linked to neoplasm.